Viruses 2014, 6(8), 3293-3310; doi:10.3390/v6083293
Article

Fiber-Modified Adenovirus for Central Nervous System Parkinson’s Disease Gene Therapy

1,2email, 3email, 2email, 2email and 4,* email
Received: 29 November 2013; in revised form: 22 July 2014 / Accepted: 27 July 2014 / Published: 21 August 2014
(This article belongs to the Special Issue Adenoviral Vectors)
View Full-Text   |   Download PDF [6601 KB, uploaded 21 August 2014]
Abstract: Gene-based therapies for neurological diseases continue to develop briskly. As disease mechanisms are elucidated, flexible gene delivery platforms incorporating transcriptional regulatory elements, therapeutic genes and targeted delivery are required for the safety and efficacy of these approaches. Adenovirus serotype 5 (Ad5)-based vectors can carry large genetic payloads to provide this flexibility, but do not transduce neuronal cells efficiently. To address this, we have developed a tropism-modified Ad5 vector with neuron-selective targeting properties for evaluation in models of Parkinson disease therapy. A panel of tropism-modified Ad5 vectors was screened for enhanced gene delivery in a neuroblastoma cell line model system. We used these observations to design and construct an unbiased Ad vector platform, consisting of an unmodified Ad5 and a tropism-modified Ad5 vector containing the fiber knob domain from canine Ad serotype 2 (Ad5-CGW-CK2). Delivery to the substantia nigra or striatum showed that this vector produced a neuronally-restricted pattern of gene expression. Many of the transduced neurons were from regions with afferent projections to the injection site, implicating that the vector binds the presynaptic terminal resulting in presynaptic transduction. We show that Ad5-CGW-CK2 can selectively transduce neurons in the brain and hypothesize that this modular platform is potentially adaptable to clinical use.
Keywords: gene therapy; adenovirus; brain; CNS; Parkinson disease
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Lewis, T.B.; Glasgow, J.N.; Harms, A.S.; Standaert, D.G.; Curiel, D.T. Fiber-Modified Adenovirus for Central Nervous System Parkinson’s Disease Gene Therapy. Viruses 2014, 6, 3293-3310.

AMA Style

Lewis TB, Glasgow JN, Harms AS, Standaert DG, Curiel DT. Fiber-Modified Adenovirus for Central Nervous System Parkinson’s Disease Gene Therapy. Viruses. 2014; 6(8):3293-3310.

Chicago/Turabian Style

Lewis, Travis B.; Glasgow, Joel N.; Harms, Ashley S.; Standaert, David G.; Curiel, David T. 2014. "Fiber-Modified Adenovirus for Central Nervous System Parkinson’s Disease Gene Therapy." Viruses 6, no. 8: 3293-3310.


Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert